Trial record 33 of 2224 for:    Melanoma

A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01782508
Recruitment Status : Unknown
Verified January 2013 by Lu Si, Beijing Cancer Hospital.
Recruitment status was:  Recruiting
First Posted : February 4, 2013
Last Update Posted : February 4, 2013
Information provided by (Responsible Party):
Lu Si, Beijing Cancer Hospital

Brief Summary:
The purpose of this study is to compare the relapse free survival and overall survival of Imatinib (Gleevec) or high dose Interferon (Intron) in treating melanoma which has primary tumor and regional lymphonode (if have) removed in patients whose disease carries a c-kit mutation. It is assumed that Gleevec may be more effective on relapse free survival as the adjuvant treatment compared with Interferon.

Condition or disease Intervention/treatment Phase
Melanoma Drug: imatinib Drug: Interferon Phase 2

Detailed Description:
If mutation tests show that the patient is eligible and they choose to participate in the study, they will be randomized and receive imatinib/Interferon. Each imatinib pill will be 100mg and the participants will take 4 pills once daily (400mg).Participants randomized to the interferon arm will receive Interferon 1500wiu/m2 d1-5 for 4 weeks followed by 900wiu IH TIW for 11 months. The following study procedures will also be performed at routine intervals throughout the course of treatment including blood tests, medical history updates, physical exams and Chest/Abdomen/Pelvic CT examinations.Participants will be on this study for one year and then be followed up to relapse or distal metastasis.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Randomized Study of Imatinib Versus High Dose Interferon as Adjuvant Therapy in KIT-mutated Patients With Resected Melanoma
Study Start Date : August 2012
Estimated Primary Completion Date : December 2013
Estimated Study Completion Date : December 2014

Arm Intervention/treatment
Experimental: imatinib
Participants will take 400mg tablets once daily for one year
Drug: imatinib
a selectively inhibits the KIT protein tyrosine
Other Name: gleevec

Active Comparator: inteferon
Participants will receive Interferon 1500wiu/m2 d1-5for 4 weeks followed by 900wiu IH TIW for 11 months
Drug: Interferon
Interferon belongs to the large class of glycoproteins known as cytokines.
Other Name: Intron

Primary Outcome Measures :
  1. relapse free survival [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 18 months ]

Secondary Outcome Measures :
  1. overall survival [ Time Frame: From date of randomization until the date of death from any cause, assessed up to 48 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Melanoma patients whose primary tumor and regional lymphonodes (if have)have been resected
  • Histologically documented AJCC stage IIB to IIIC
  • C-kit mutation documented from either primary or metastatic lymphnode site
  • ECOG performance status 0 or 1
  • Age 18 years or older
  • Creatinine < 1.5 x ULN
  • ANC > 1500 ul
  • Platelets > 100,000 ul
  • Total bilirubin, AST, and ALT < 2 x ULN
  • Amylase and lipase < 1.5 x ULN
  • no prior chemotherapy or investigational drug

Exclusion Criteria:

  • Severe and/or uncontrolled medical disease
  • Pregnant or nursing mothers
  • Any other significant medical, surgical, or psychiatric condition that may interfere with compliance
  • Patient is < 5 years free of another primary malignancy except: basal cell skin cancer or a cervical carcinoma in situ
  • Concurrent treatment with Warfarin
  • Prior treatment with c-kit inhibitor
  • Patient with Grade III/IV cardiac problems as defined by NYHA criteria
  • No H2 blockers or proton pump inhibitors
  • Known chronic liver disease
  • Known diagnosis of HIV infection
  • Major surgery within 2 weeks prior to study entry
  • Patient has received any other investigational agent within 28 days of first study drug dosing
  • Chemotherapy within 4 weeks prior to study entry

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01782508

Contact: Lu Si, MD +86(10)88196951

Beijing Cancer Hospital Recruiting
Beijing, China, 100142
Contact: Lu Si, MD    +86(10)88196951   
Sub-Investigator: Lu Si, MD         
Sponsors and Collaborators
Beijing Cancer Hospital
Principal Investigator: Jun Guo, M.D. Beijing Cancer Hospital

Responsible Party: Lu Si, Associate professor, Beijing Cancer Hospital Identifier: NCT01782508     History of Changes
Other Study ID Numbers: AMN107A2301
First Posted: February 4, 2013    Key Record Dates
Last Update Posted: February 4, 2013
Last Verified: January 2013

Keywords provided by Lu Si, Beijing Cancer Hospital:
melanoma,adjuvant therapy,kit mutated melanoma

Additional relevant MeSH terms:
Nevi and Melanomas
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Imatinib Mesylate
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action